Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04752137 · ClinicalTrials.gov registry record · Phase 2
Intraoperative Tumor Margin Identification With ICG Dye Imaging
A Phase 2 study of Malignant Neoplasm and Benign Neoplasm, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT04752137 is a Phase 2 study of Malignant Neoplasm and Benign Neoplasm that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 100 participants, below the 512-participant average among 59 other Malignant Neoplasm trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04752137, a Phase 2 study of Malignant Neoplasm and Benign Neoplasm, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
In this research study we want to learn more about the use of indocyanine green (ICG) during bone or soft tissue mass resections. Indocyanine green (ICG) is a type of dye that is used in medical diagnostics. We want to determine if ICG-guided tumor resection is more effective in obtaining negative margins. Lastly, we want to assess traditional oncologic outcomes of local recurrence, time to metastatic disease, and overall and disease specific survival.
Conditions Studied
Interventions
- DRUG Indocyanine green
- DEVICE SPY-PHI
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2022-05-25 |
| Est. Completion | 2026-10-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04752137
The ClinicalTrials.gov registry entry for NCT04752137 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 512-participant average among 59 other Malignant Neoplasm trials with a reported enrollment target (80% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Malignant Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which Indocyanine green is the first listed.
NCT04752137 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04752137 about?
NCT04752137 is a clinical study titled "Intraoperative Tumor Margin Identification With ICG Dye Imaging". In this research study we want to learn more about the use of indocyanine green (ICG) during bone or soft tissue mass resections. Indocyanine green (ICG) is a type of dye that is used in medical diagnostics. We want to determine if ICG-guided tumor resection is more effective in obtaining negative m...
What is the current status of trial NCT04752137?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2022-05-25. Estimated completion is 2026-10-01.
What conditions does trial NCT04752137 study?
This clinical trial studies the following conditions: Malignant Neoplasm, Benign Neoplasm.
What interventions are being tested in trial NCT04752137?
The interventions under investigation include: Indocyanine green (DRUG), SPY-PHI (DEVICE).
Who is sponsoring clinical trial NCT04752137?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04752137 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
RECRUITING · Phase 2
-
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
RECRUITING · Phase 2
-
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
RECRUITING · Phase 2
-
Dexamethasone in Controlling Dyspnea in Patients With Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies
ACTIVE NOT RECRUITING · Phase 2
-
Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.